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Abstract
Metabolic syndrome describes a set of obesity-related disorders that increase diabetes,
cardiovascular, and mortality risk. Studies of liver-specific protein-tyrosine phosphatase 1b
(PTP1b) deletion mice (L-PTP1b−/−) suggest that hepatic PTP1b inhibition would mitigate
metabolic-syndrome through amelioration of hepatic insulin resistance, endoplasmic-reticulum
stress, and whole-body lipid metabolism. However, the altered molecular-network states
underlying these phenotypes are poorly understood. We used mass spectrometry to quantitfy
protein-phosphotyrosine network changes in L-PTP1b−/− mouse livers relative to control mice on
normal and high-fat diets. We applied a phosphosite-set-enrichment analysis to identify known
and novel pathways exhibiting PTP1b- and diet-dependent phosphotyrosine regulation. Detection
of a PTP1b-dependent, but functionally uncharacterized, set of phosphosites on lipid-metabolic
proteins motivated global lipidomic analyses that revealed altered polyunsaturated-fatty-acid
(PUFA) and triglyceride metabolism in L-PTP1b−/− mice. To connect phosphosites and lipid
measurements in a unified model, we developed a multivariate-regression framework, which
accounts for measurement noise and systematically missing proteomics data. This analysis
resulted in quantitative models that predict roles for phosphoproteins involved in oxidation-
reduction in altered PUFA and triglyceride metabolism.
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Introduction
Metabolic syndrome encompases a group of commonly associated disorders, including
central obesity, hyperglycemia, hyperinsulinemia, dyslipidemia, and hypertension, that
promote the development of type 2 diabetes mellitus (T2DM) and cardiovascular disease
(CAD)1, 2. In tandem with obesity, metabolic syndrome and its co-morbidities have spread
worldwide, affecting individuals across all socioeconomic circumstances3. Liver is a
prominent contributor to metabolic syndrome pathogenesis and a primary target tissue for
therapeutic intervention4. In the context of metabolic syndrome, hepatic insulin resistance
results in excess gluconeogenesis, hyperglycemia, and hyperinsulinemia. In addition, liver
accumulates lipid as a result of free fatty acid (FFA) flux from insulin-resistant adipose
tissue and altered hepatic lipid metabolism. Accumulation of hepatic lipid is often associated
with inflammation and compromised liver function. Although the detailed mechanisms of
insulin resistance remain the subject of intense debate, there is a consensus that insulin
resistance develops from impaired cellular signaling downstream of the insulin receptor
(IR)5.
Considerable interest has developed in protein tyrosine phosphatase 1b (PTP1b) as a
therapeutic target to potentiate insulin signaling in the context of metabolic syndrome.
PTP1b is a ~50kDa protein anchored to the cytoplasmic face of the endoplasmic reticulum
(ER) and is a well-established negative regulator of insulin signaling, via dephosphorylation
of tyrosine residues on IR, and leptin signaling, via dephosphorylation of tyrosine residues
on Janus kinase 2 (Jak2)6. Accordingly, whole-body PTP1b−/− mice are lean, hypersensitive
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to insulin, and resistant to diet-induced obesity7. In addition, PTP1b regulates specific
phosphotyrosine sites on proteins in other pathways (Src, MAPK, cell adhesion and
motility)6, which might also physiologically impact PTP1b−/− mice.
Liver-specific PTP1b-deletion mice (L-PTP1b−/−) are not resistant to diet-induced obesity,
but hepatic PTP1b deletion enhances insulin signaling8. Thus, L-PTP1b−/− mice have
improved postprandial suppression of hepatic glucose production, which contributes to
whole-body glucose homeostasis in the context of high-fat diet (HFD). In addition, on HFD,
hepatic PTP1b deficiency drives positive lipid metabolic changes in both liver and
circulation, consistent with improved liver health and reduced cardiovascular risk8. Finally,
when challenged by HFD or ER-stress inducers such as tunicamycin and thapsigargin, L-
PTP1b−/− mice have a muted hepatic ER stress response across all three major ER-stress
sensing pathways8, 9. These phenotypes are therapeutically attractive given the importance
of ER stress to metabolic syndrome pathogenesis, especially in the context of hepatic
inflammation and lipotoxicity10, 11. Thus, in terms of whole-body and liver-specific
physiology, PTP1b inhibition holds therapeutic potential for treatment of metabolic
syndrome12.
Although hepatic PTP1b inhibition or deletion has been associated with positive
physiological effects, the underlying molecular network alterations are not well understood.
To address this issue, we coupled statistical modeling techniques with quantitative mass-
spectrometry (MS) measurements of hepatic protein tyrosine phosphorylation to determine,
in an unbiased and site-specific manner, the phosphotyrosine network alterations mediating
resistance to HFD-induced stress in L-PTP1b−/− mice. These studies revealed that hepatic
phosphotyrosine networks are sensitive to both PTP1b deletion and HFD, and that the
PTP1b-dependent phosphorylation sites are significantly enriched for enzymes with diverse
metabolic functions, including lipid metabolism. To elucidate a role for this largely
uncharacterized set of PTP1b-dependent phosphosites on lipid metabolic proteins, we
globally profiled hepatic lipids and found that hepatic PTP1b deletion alters metabolism of
fatty acids and triglycerides. To determine the phosphorylation network states associated
with altered lipid metabolism, multivariate statistical models were developed that integrate
our lipidomic and proteomic observations. These models highlight the molecular
underpinnings connecting PTP1b deletion, altered tyrosine phosphorylation signaling, and
altered lipid metabolism, and also offer quantitative predictions for selected network
perturbations.
Results
Study design
L-PTP1b−/− mice were generated by crossing PTP1b-floxed (PTP1b-fl/fl) mice with mice
expressing Cre recombinase under the control of the albumin promoter (Alb-Cre), resulting
in Alb-Cre PTP1b-fl/fl mice that specifically lack hepatic PTP1b8. Twenty-one L-PTP1b−/−
and 28 Alb-Cre control mice were fed a normal chow (NC) diet (14% kcal from fat) until 12
weeks of age, at which point half of the mice were placed on HFD (55% kcal from fat) and
the rest continued on NC. These diets were maintained until 19.5 weeks of age (Figure 1A).
To gauge the physiological consequences of HFD, serum markers of insulin sensitivity and
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lipid metabolism were measured at 17.5 and 18.5 weeks (Table S1). As expected, both L-
PTP1b−/− and control mice had elevated levels of fed insulin and glucose on HFD relative
to NC, indicating that insulin resistance developed during the course of the diets. While L-
PTP1b−/− and control mice had similar fed glucose and insulin for a given diet, L-PTP1b−/
− mice had significantly elevated fasted glucose relative to controls on both diets.
At 19.5 weeks, mice were sacrificed and their livers were flash-frozen for biochemical
analysis. To determine the molecular effects of PTP1b deletion and HFD on insulin
response, liver was harvested under either basal or insulin stimulation conditions (Figure
1A). Each combination of experimental conditions (genotype, diet, and stimulation)
included 3–8 mice, thereby enabling statistical analysis for each condition.
HFD and genotype drive global phosphotyrosine network changes
Relative quantification of protein phosphotyrosine levels across each individual liver sample
was accomplished by combining results from ten 8-plexed, phosphotyrosine-
immunoprecipitation (IP)-Immobilized Metal Affinity Chromatography (IMAC)-Liquid
Chromatography (LC)-Tandem MS (MS/MS) experiments (Figure 1B)13. This analysis
resulted in the identification and quantification of 298 tyrosine phosphosites on 206
proteins; measurement error from available technical replicates was ~10% (Table S2,
Methods). To visualize the most important trends across the multidimensional
phosphotyrosine datasets, we applied principal component analysis (PCA). The most
dominant phosphosite trends dictate the locations of liver samples in the principal
component plane, and here the plane naturally segregates livers according to diet and
genotype conditions for both the insulin-stimulated and basal datasets (Figure 2A). This
suggests that diet and genotype are the dominant causes of phosphotyrosine network
perturbations; individually, genotype and diet explain 21–23% and 15–17% of the
phosphorylation variance. The PCA plot demonstrates that the phosphorylation data alone is
sufficient to distinguish genotype and diet among the various mice.
Correlation-based statistical analysis was used to detect and order PTP1b-dependent and
diet-dependent phosphorylation sites in heat maps (Figures 2B and S1). Due to the
stochastic nature of data-dependent MS analysis14, the dataset is somewhat sparse, with
many of the phosphorylation sites measured in only some of the MS experiments. However,
using correlation-based analysis, we identified large clusters of PTP1b-dependent and diet-
dependent sites. It is important to note that alterations in the phosphorylation network reflect
rewiring of the signaling network over time, leading to increased phosphorylation on some
sites and decreased phosphorylation on others in response to chronic hepatic PTP1b
deletion. In agreement with this interpretation, RNAseq analysis of a subset of livers
revealed no significant gene expression changes for the phosphoproteins detected in our
study (significant controlling for FDR < .05, n = 2 pooled L-PTP1b−/− samples, n = 2
pooled control samples, where each pooled sample was composed of 3–4 independent livers,
data not included), suggesting that the alterations in protein tyrosine phosphorylation were
post-transcriptional.
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PTP1b-dependent phosphosites are enriched among insulin signaling, REDOX, and lipid
metabolic pathways
We adapted a gene set enrichment analysis (GSEA) framework15 for an integrated,
pathway-level analysis of our quantitative protein phosphorylation data; this approach
identified several protein pathways that were enriched for PTP1b-dependent
phosphotyrosine regulation. In total, we tested for PTP1b-dependence in 59 hand-curated
phosphosite sets (Table S3), composed of protein pathway annotations from Kegg, cellular
locations from GO, protein structural information (PFAM and SwissPro), a curated list of
PTP1b substrates16, as well as a set of insulin-sensitive phosphorylation sites from a
previous study17. In this analysis, the direction of PTP1b-dependence was taken into
account, as we searched for phosphosite sets that showed a concordant increase or decrease
in phosphorylation upon PTP1b deletion. Seven phosphosite sets showed significant PTP1b-
dependent tyrosine phosphorylation (FDR<0.01, Table S4). Consistent with its role in
regulating insulin sensitivity, phosphosites involved in insulin signaling had increased
phosphorylation upon PTP1b deletion; these include sites on the receptor (IR), receptor
substrates (IRS1, IRS2, Shc), and several other canonical insulin signaling proteins (PI3K,
Erk1, Erk2, and others). Enrichment of PTP1b-dependent phosphosites on proteins localized
to the ER and cytosol was in agreement with the cellular localization of PTP1b to the
cytoplasmic face of the ER, providing additional confirmation that our approach identified
relevant connections among the PTP1b-dependent sites.
In our analysis, we detected and quantified phosphorylation of eleven of the 18 PTP1b
substrate proteins and seven of the 25 PTP1b-substrate phosphosites reported by Ren et
al.16. These sets of phosphorylation sites were tested for PTP1b-dependence, but neither set
was significantly enriched among PTP1b-dependent phosphosites. The lack of PTP1b-
dependent phosphorylation on some PTP1b substrates suggests compensatory modes of
regulation (e.g. through other PTPs and kinases) and that the PTP1b-dependent phenotypes
are due to phosphorylation changes on additional proteins and pathways. The complexity of
the biological response to PTP1b deletion makes it challenging to identify direct substrates
of PTP1b from our experimental design, but the network-level phosphosite measurements
provide direct insight into the particular proteins and pathways that are modulated by PTP1b
deletion or HFD and thereby contribute to altered physiological states in vivo.
Our unbiased, network-level approach identified several novel sets of PTP1b-dependent
phosphosites, including those on proteins involved in metabolic processes, oxidation-
reduction (REDOX) and lipid metabolism. Given that beneficial lipid metabolic changes had
been previously reported in L-PTP1b−/− mice on HFD8, the PTP1b-dependent increase in
phosphorylation of lipid metabolic proteins (highlighted in Figure 2B) was of particular
interest. These proteins spanned a diverse set of lipid pathways, including fatty acid (FA)
metabolism and transport (acyl-coA binding protein (ACBP), FA synthase (FAS), ATP
citrate lyase (ACLY), cytochrome b5 (CYB5A), and cytochrome P450 2e1 (CYP2E1)),
triglyceride (TG) synthesis, storage and transport (long-chain fatty acid-CoA ligase 5
(ACSL5), high-density-lipoprotein binding protein (vigilin)) and phospholipid metabolism
and transport (peroxiredoxin 6 (PRDX6), staphylococcal nuclease and tudor domain-
containing 1 (SND1), S-adenosyl homocysteine hydrolase (SAHH)). Independently, the set
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of phosphosites limited to proteins involved in FA metabolism was also significantly
PTP1b-dependent (FDR<0.05), highlighting potential PTP1b-dependent regulation of FAs
in particular. Some of these phosphorylation sites have been identified in previous large-
scale studies, but their functions have not been characterized.
The enrichment of PTP1b-dependent phosphosites on REDOX proteins is intriguing given
that oxidative stress plays an important role in obesity-induced ER stress and
inflammation18. These phosphorylation sites are on proteins typically thought of as
metabolic enzymes rather than signaling molecules (e.g., 4-hydroxyphenylpyruvic acid
dioxygenase (HPD) Y221, aldehyde dehydrogenase 1a7 (ALDH1A7) Y484, see (Table S4)),
and the functions of these sites as well as the contributions of these proteins to ER stress and
inflammation are largely uncharacterized. Although numerous and diverse metabolic
enzymes are expressed in liver tissue, enrichment for metabolic proteins among PTP1b-
dependent phosphosites was unexpected. In addition to REDOX and lipid metabolic
proteins, other metabolic processes that show PTP1b-dependent phosphorylation (FDR < .
05) include arginine and proline metabolism, phenylalanine metabolism, and glycolysis/
gluconeogenesis (Table S4). The functions and PTP1b-dependent regulation of these
phosphorylation sites are unexplored. However, recent work demonstrates that site-specific
tyrosine phosphorylation of other metabolic enzymes critically modulates enzyme activity,
affecting metabolism, REDOX environment, and growth at the cellular level19, 20.
In contrast to PTP1b-dependent sites, phosphosite set enrichment analysis of diet-dependent
sites yielded a single significant enrichment for mitochondrial proteins (FDR < .01, Table
S5, highlighted in Figure S1) (note that the scarcity of significant enrichments reflects MS
experimental design rather than a lack of pathway-specific HFD-mediated phosphotyrosine
changes (discussed in Methods)). Tyrosine phosphorylation of mitochondrial proteins has
been implicated in the context of cancer, as oncogenic RTKs and Src family kinases have
been shown to translocate to the mitochondria and directly phosphorylate and modulate
mitochondrial metabolic enzymes21, 22. Interestingly, our analysis indicates that HFD also
increases tyrosine phosphorylation on mitochondrial proteins, suggesting a potential link
between cancer and obesity. Further investigation of these phosphorylation sites might
reveal specific mechanisms by which obesity promotes cancer metabolism.
PTP1b-deficient livers have an overabundance of free PUFAs
Although lipid and FA metabolic pathways show significant PTP1b-dependent
phosphotyrosine regulation, the effects of these network changes have not been
characterized. To gain insight into the potential roles of these sites and determine whether
altered phosphorylation impacts hepatic lipid composition, we performed quantitative
lipidomic analyses of the livers. Given the diversity of lipid metabolic proteins with PTP1b-
dependent phosphorylation, we applied a global LC-MS-based lipidomic strategy that
enables de novo discovery of differentially abundant lipids among samples (Figure 3)23.
Using this approach, we quantitatively monitored lipids and found several differences
between L-PTP1b−/− and control mice. On HFD, the most significantly PTP1b-dependent
lipids were polyunsaturated FAs (PUFAs) in the free-FA (FFA) pool. To examine these
changes more closely, a calibration curve, composed of isotopically labeled FA standards,
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was used to more accurately quantify FAs detectable by our method (28 structural isomers,
ranging from C16 to C24 acyl-chain lengths and spanning four orders of magnitude in
abundance (Methods)). Interestingly, PTP1b deletion altered the FA pool composition rather
than pool size, as total FAs were similar between L-PTP1b−/− and control mice (Table S6).
To visualize these results, we plotted each FA on a volcano plot as a function of
compositional fold-change (L-PTP1b−/− relative to control) and corresponding statistical
significance (Figure 4A). Many of the unsaturated FAs had ion chromatogram elution
profiles with multiple peaks (Figures 3B and S2); each peak corresponds to a particular
isomer whose elution time is dependent on the position of the final (ω) double bond in the
acyl chain. Double-bond location is a critical determinant of physiological function. For
example, C20:3 ω6 is the anti-inflammatory lipid dihomo-γ-linolenic acid, whereas C20:3
ω3 is a precursor of the anti-lipogenic PUFAs eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA). The physiological roles of C20:3 ω7 and ω9, on the other
hand, are less-well studied. As can be seen in the upper-right-hand corner of Figure 4A,
several PUFAs were significantly increased in the L-PTP1b−/− livers, including C18:3,
C20:3, C22:3. Particular isomer peaks for each of these PUFAs were PTP1b-dependent, and
thus determination of double bond location was necessary to understand the physiological
implications of these changes.
To identify PTP1b-dependent C18:3, C20:3 and C22:3 isomer peaks, co-injection
experiments with commercially available isomer standards were performed (Figure S2).
Because standards were not available for confirmation of all assignments, uncertainty in ω-
bond assignment is denoted with an asterisk. The most significantly PTP1b-dependent
PUFA (C18:3, C20:3, and C22:3) species were ω9 or a combination of ω9 and ω7 species
and, in addition to total C20:2, are referred to as “ω7+ω9 PTP1b-dependent PUFA”
(denoted in red, Figure 4A). The other PTP1b-dependent PUFA species (C24:6, C24:5,
C24:4, C20:3, C22:3, colored in green in Figure 4A) were ω3 and ω6 and are referred to as
“ω3+ω6 PTP1b-dependent PUFA”.
To gain insight into the unknown physiological functions of the PTP1b-dependent PUFA
isomers, correlation-based clustering was applied to the percent FA compositions of HFD
and NC livers. PTP1b-dependent PUFA clustered with several better-characterized PUFA
(Figure 4B). All ω3+ω6 PTP1b-dependent PUFA, including the poorly characterized C24
PUFA series, cluster with PUFAs with known physiological roles, including anti-lipogenic/
anti-inflammatory DHA (C22:6 ω3) and EPA (C20:5 ω3), for which the ω3 PTP1b-
dependent PUFAs (C18:3, C20:3, and C24:6) would all be precursors. As might be
expected, this cluster of PUFAs, several of which are associated with physiological benefit,
is significantly depleted in the HFD livers relative to NC (Table S6). The high level of
correlation between the FAs in this cluster suggests a beneficial metabolic function for the
ω3+ω6 PTP1b-dependent PUFAs.
By contrast, the C20:3 ω9/ω7* isomers were barely detectable in NC livers, and the C18:3
ω7* and C22:3 ω9*/ω7* isomers were not detected (Table S6), suggesting that these species
are byproducts of HFD metabolism. C20:3 ω9/ω7* clusters with C20:2 and
monounsaturated FAs (MUFAs): C16:1 ω7, C18:1 ω9 and C20:1 (Figures 4B). Given that
ω7/ω9 MUFA are products of the Δ9 desaturase, stearoyl-CoA desaturase (SCD), the C18
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SCD Index, the ratio of SCD’s major product (oleic acid) to substrate (stearic acid), which is
often used as a surrogate for SCD activity24, was calculated for all livers. In agreement with
the increased abundance of the ω7+ω9 PTP1b-dependent PUFAs, the SCD Index is elevated
in both NC and HFD L-PTP1b−/− mice relative to control under basal conditions (Figure
4C). At the condition examined (10mU/g, 10 min.), insulin stimulation did not affect the
SCD index for control mice, however, the SCD index of L-PTP1b−/− livers was reduced
upon stimulation, suggesting an insulin-dependent effect. Indeed, the insulin dose was
hypoglycemia-inducing, and, given that the L-PTP1b−/− livers are more sensitive to insulin,
it is possible that L-PTP1b−/− mice became hypoglycemic more quickly, leading to rapid
suppression of SCD activity via hypoglycemic stress response. In support of insulin-induced
hypoglycemic stress, the ratio of pT172 AMPK to total AMPK is elevated in some of the
insulin-stimulated livers (Figure 4D). These results suggest that L-PTP1b−/− mice might
have increased hepatic SCD activity under normal physiological conditions.
PTP1b-deficient livers have altered triglyceride metabolism on HFD
MS-based lipidomics analysis revealed that L-PTP1b−/− mice have an approximately 2-fold
increase in total hepatic TGs relative to control mice on HFD (Fig. 5A). This trend was
verified in quantitative MS-lipidomics analyses (with TG standard) and further validated
with a more conventional, enzymatic assay, which correlated well with MS results (ρ = .96).
These results were unexpected, given that we previously found a decrease in L-PTP1b−/−
hepatic TGs on HFD at an early time point (8 weeks of age) and no difference at 21 weeks, a
time point more similar to this study (19.5 weeks)8. To verify that the trends were
reproducible at this timepoint, liver TGs were quantified in a second cohort of HFD mice (4
L-PTP1b−/−, 4 control). These additional samples confirmed that hepatic TGs were elevated
in L-PTP1b−/− mice (combined data shown in Figure 5A). These data are even more
striking when liver TG content is plotted as a function of mouse weight. For weight-matched
pairs of mice, L-PTP1b−/− mice have dramatically more hepatic TG content (Figure 5B),
and there is surprisingly little correlation between total hepatic and serum TGs (Figure 5C).
This disparity between hepatic and serum TGs is consistent with the later time point in our
previous study8, where L-PTP1b−/− mice had significantly lower serum TGs but similar
hepatic TGs relative to control mice. The lack of correlation between hepatic and serum TGs
in both studies suggests a PTP1b-dependent defect in hepatic TG secretion that increases
with age.
Because liver steatosis is often implicated in compromised liver function and inflammation,
we measured molecular markers of inflammation: IL-6 and IL-1b, the marker of
macrophage infiltration MCP-1, and phosphorylation of the stress kinase p38 (Figure S3).
Despite elevated steatosis, we did not detect increased inflammation in the L-PTP1b−/−
mice, which is consistent with the muted ER stress and inflammation responses observed in
these mice previously8, 9.
In addition to total TGs, MS analysis provided quantification for 26 TG structural isomers,
characterized by the sum of carbons and double bonds in the acyl chains (Table S7).
Detected TGs ranged from 48 to 56 total acyl carbon length and contained a total of one to
ten double bonds. Statistically significant PTP1b-dependent changes in TG composition
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were visualized in a volcano plot (Figure 5D). As a fraction of the total pool, TGs with many
sites of desaturation, or “PUFA-rich” TGs, are specifically reduced in L-PTP1b−/− livers
relative to control. Notably, the number of double bonds in the TGs correlates with the
compositional depletion of that TG in the L-PTP1b−/− livers (P<10−5).
Longer-chain, PUFA-rich TGs constitute a larger percentage of TG composition in NC
relative to HFD mice, regardless of genotype. As highlighted by the heatmap of clustered
TG compositions (Figure 5E), the distinction between NC abundance and HFD depletion of
these metabolites is much more pronounced than the compositional difference between HFD
L-PTP1b−/− and control mice. On HFD, esterification of diet-derived FAs into TGs may
limit their cytotoxic effects. The resulting build-up of shorter-chain TGs with fewer sites of
desaturation would explain the lower fraction of longer-chain, PUFA-rich TGs in HFD
versus NC mice.
The physiological significance of the liver TG compositions in L-PTP1b−/− mice on HFD is
unknown, but serum depletion of PUFA-rich TG species is positively predictive of T2DM
development in humans25. To determine whether the compositional depletion of PUFA-rich
TGs in the L-PTP1b livers was associated with similar serum compositional changes, we
assayed serum TGs by MS (Table S8, Figure S4) and detected a parallel depletion in PUFA-
rich TGs (P<10−10, correlation between TG double bond number and depletion in L-PTP1b
−/− mice).
Although total liver and serum TG measurements suggest a TG secretion defect, the altered
TG compositions (depletion of PUFA-rich and elevation of MUFA-rich TGs) suggest that
elevated hepatic lipogenesis might also contribute to liver steatosis in the L-PTP1b−/− mice
on HFD. For this reason, we measured the ratio of pS79 acetyl-CoA carboxylates (ACC) to
total ACC, a marker of lipogenesis inhibition (Figure S5). Although total pS79 ACC was
significantly increased in L-PTP1b−/−, the ratio of pS79 ACC to ACC was not significantly
elevated. These data, as well as the lipogenic mRNA expression measurements in the
previous study (Delibegovic et al, 2009), suggest that lipogenesis is not increased in the L-
PTP1b−/− livers. Thus, the compositional TG changes in L-PTP1b−/− mice might reflect an
increased capacity to store diet-derived FAs as neutral TGs. Altered acyl chain compositions
in other complex lipid classes (e.g., phospholipids) were not detected.
Modeling the relationships between protein phosphorylation and lipid metabolites:
incorporation of measurement noise with stochastic multivariate regression
To gain insight into the phosphosites that might potentiate PTP1b-dependent phenotypes, we
constructed computational models from the phosphorylation and lipid measurements. Given
the size of our study and the limited functional annotation for most of the quantified lipids
and phosphosites, we built multivariate regression models that take advantage of mouse-
specific profiles to predict the novel PTP1b-dependent phenotypes. As PTP1b-dependent
phosphotyrosine network alterations were likely drivers of the observed lipid metabolic
changes, our model-building efforts focused on predicting lipid metabolic phenotypes
(steatosis, ω7+ω9 PTP1b-dependent PUFA, and the ω3+ω6 PTP1b-dependent PUFA) as
functions of the 228 phosphosites in the HFD basal (HFDB) dataset. However, prior to
building the models, we considered strategies to combat two technical challenges inherent to
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this dataset and large-scale, MS-based proteomics datasets in general: (1) measurement error
and (2) systematically missing data points, the latter of which results from the stochastic
nature of data-dependently acquired MS/MS spectra, as noted earlier. Frameworks for
building multivariate regression models in the context of these challenges are described and
evaluated here and in the subsequent section.
The error associated with mouse-specific phosphorylation measurements ranges from ~1–
70% (Figure S6A). Measurement noise can lead to spurious correlation, especially for
phosphosites with fold-changes smaller than measurement error. Although it might be
possible to remove some of these noisy phosphosites using ANOVA (i.e., by filtering out
sites whose phosphorylation is statistically unchanging across samples in the dataset), the
selection of a cutoff for data inclusion is often difficult to justify. Thus, in order to
distinguish biological variation from measurement noise in the model-building process, we
developed stochastic multivariate regression (SMR). The SMR method uses Monte Carlo
sampling26 followed by bootstrapping26 to develop a distribution of regression coefficients
that incorporate measurement error in the context of limited sample size. The coefficient
distribution can then be used to evaluate the significance of predictor variables to the model.
In the Monte Carlo sampling step, Gaussian distributions are used to model phosphosite-
levels, and these distributions (one for each data-point) are based on experimental means
and error estimates from technical replicates (Figure S6B). Intuitively, the Monte Carlo
sampling step penalizes noisier predictor-response (phosphosite-lipid) measurements, as
large measurement errors will be reflected in wider coefficient distributions and thus less-
significant p-values or variable importance of project (VIP) scores, two metrics of predictor
importance used in model variable-selection procedures.
The ability of SMR to account for measurement error is highlighted in a comparison to
multivariate regression where the Monte Carlo sampling step is skipped (deterministic
multivariate regression, DMR) and measurement error is not incorporated into the
regression- coefficient significances. Three multivariate linear regression models (of
Genotype (discriminating L-PTP1b−/− livers from control), Steatosis, and C18 SCD Index)
were constructed using the complete HFDB data subset (76 sites × 13 samples). The overlap
between phosphosites selected for the three models by SMR and DMR are shown with
ANOVA-filtered phosphosites in Venn diagrams (Figure 6A). Unlike DMR-selected
variables, SMR-selected variables are a subset of the ANOVA-filtered phosphosites,
suggesting that measurement noise is properly reflected in regression-coefficient
significances. The three response variables Genotype, Steatosis, and C18 SCD Index have
estimated relative standard errors of ~0, 16% and 32%. As the standard error of the response
variable increases, the number of phosphosites with significance regression coefficients
decreases for SMR models, relative to DMR models. Ultimately, no phosphosites are
significantly associated (Praw < .05) with the response variable with the greatest standard
error, C18 SCD Index, because the error in this measurement, in combination with
phosphosite measurement errors, is too great. ANOVA-filtering of the phosphosites would
not have substituted for SMR in this case, as the dominant measurement error was in the
response. Through the SMR method, measurement error from both predictor and response
variables is reflected in the significances of resulting regression coefficients derived from
the bootstrapped distributions of regression coefficients.
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Modeling the relationships between protein phosphorylation and lipid metabolites:
optimization of missing data methods for multivariate regression
The second consideration for multivariate regression modeling with MS-based proteomics
datasets is systemically missing data points. In contrast to the univariate correlation-based
methods pursued above, multivariate regression requires that a dataset be complete. MS-
based proteomics datasets can pose a significant challenge, due to the number of
systematically missing data points that result from merging multiple data-dependently
acquired MS experiments. As a specific example, the HFDB data matrix is displayed in
Figure 6B. Because the data points are systematically missing, data methods based on matrix
decomposition, which work well in the context of multivariate regression by partial least
squares, were not feasible27. \
To address the issue of systemically missing data points, we considered several missing data
methods. First, we evaluated “list-wise deletion” of all measurements for which sample
coverage was incomplete, a method used in previous multivariate regression analyses of
MS-based phosphotyrosine measurements28, 29. Although this method requires no
assumptions or ad hoc rules, the final size of the dataset is reduced to only those sites for
which quantification is available for all conditions. In the case of the HFDB dataset, analysis
would be limited to 76 phosphorylation sites, instead of the full 228 identified sites (Figure
6B). To incorporate a larger proportion of the data into the analysis, we considered another
approach, in which multiple complete data subsets (Figure S7A) are used to build separate
models; variable rankings from the individual models are then integrated using decision
rules. In this way, data imputation is avoided; however, on the other hand, decision rules are
often heuristic rather than optimal. Finally, we evaluated imputation methods. The goal of
an imputation method is to facilitate analysis while minimizing bias, and multiple random
imputation (MRI) fulfill this criteria30. We considered traditional MRI30, and a related
method we termed “Gaussian” imputation; we also examined variations of these methods, in
which a treatment assumption (genotype-dependence) was used to impute missing data
points.
We constructed a comprehensive strategy to assess the performance of each method (Figure
6B). The complete data subset (13 samples by 76 phosphosites) was used as a reference
dataset for SMR modeling, and simulated datasets were generated by randomly removing
measurements in a pattern that structurally corresponded to the original HFDB data matrix
(Figure 6B). Three multivariate regression models, each of a different response (Steatosis,
ω3+ω6 PTP1b-dependent PUFA, and ω7+ω9 PTP1b-dependent PUFA), were built as
functions of phosphotyrosine measurements, leading to three “true” models based on SMR
of the complete data subset. Missing data methods were tested by building the same three
models using simulated datasets. Each method was evaluated based on (1) true positive rate,
the selection of phosphosites that would have been incorporated into “true” models, and (2)
false positive rate, the selection of phosphosites that were not included in the “true” models.
Results were plotted on receiver-operator characteristic (ROC) curves (Figure 6C).
For this dataset, there was significant disparity in the performance of the missing data
methods. List-wise deletion performed most poorly overall. Because this method excluded
more than two-thirds of the dataset, list-wise deletion was limited to detection of only ~30%
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of the “true” positives, at best. Even in the low-FDR regime, this method offered no
apparent benefit, as imputation methods performed equally well at low FDRs (Figure 6C).
The methods that integrated results from individual models built on complete data subsets
(“All Subsets Agree” and “Complete Subset Rules”) provided the opportunity to detect most
true positives, but at high false-positive rates. MRI-based methods performed best, with the
treatment-dependent MRI method performing best overall, suggesting that treatment-
dependent phosphorylation was a good assumption for this dataset. Importantly, the
performance of missing data methods was sensitive to the particular response modeled
(Figure 6C), suggesting that the application of missing data methods should be evaluated on
a case-by-case basis.
Integrated SMR and set-enrichment analysis yields predictive models of lipid metabolic
phenotypes and pathway-level insight from incomplete phosphotyrosine data
Final, independent models of steatosis, ω7+ω9 PTP1b-dependent PUFA, and the ω3+ω6
PTP1b-dependent PUFA were built on reduced sets of phosphosites, composed of those
phosphosites most important to model prediction (Figure 7A). Model cross-validation
indicates that these models had good predictive power (Q4 = .54, .66, .52, respectively)
(Figure 7B), especially in the context of increased biological variation in individual mouse
livers compared to cell lines, the experimental system used previously for multivariate
regression models involving MS-based phosphotyrosine measurements29, 31. It is also worth
noting that the Q4 values presented here account for both model fit and variable selection,
and thus are more conservative estimates of predictive performance than typically reported.
Most of the phosphosites highlighted by the models are uncharacterized (Figure 7A). In the
Discussion section, we use information about protein function from the literature to suggest
relationships between individual sites and effects on lipid metabolism. Although literature-
based analysis of individual model predictors revealed many interesting connections (see
below), we implemented a second strategy to gain additional insight, especially for the
predictive phosphosites on proteins whose functions were not obviously related to lipid
metabolism. Specifically, we integrated set-enrichment analysis into the multivariate
modeling framework to develop a pathway-level perspective. In general, variable reduction
methods, regardless of the specific regression technique used, rank underlying variables
(e.g., phosphosites) according to predictive potential. These ranked lists can then be used to
determine whether phosphorylation patterns on particular sets or protein pathways are
multivariately predictive and might underlie a response. Set-enrichment analyses of the three
phosphosite-dependent models (Figure 7A) highlighted the phosphorylation of REDOX
proteins as significant to each (FDR<.01, Tables S9–11); this commonality between the
predictive phosphosites was not obvious upon initial inspection of reduced-model predictors
and presents a compelling direction for future experiments. REDOX balance is a pivotal
driver of metabolic state; desaturation of FAs and CYP2E1 oxidation of PUFA, for example,
depend on conversion of NADH to NAD+. As is discussed in more detail below, oxidation
also modulates liver TG secretion and hepatic steatosis32. Therefore, net changes in cellular
oxidation and reduction mediated by tyrosine phosphorylation of REDOX enzymes could
play a significant role in lipid metabolism.
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Discussion
PTP1b inhibition continues to be a focus of drug development efforts to therapeutically
manage obesity-related diseases, and an anti-sense oligonucleotide inhibitor of PTP1b has
advanced to phase II clinical trials33. In this study, for the first time, the effect of PTP1b
inhibition on liver tissue has been characterized at the molecular network level in a broad
and unbiased manner. Using MS-based technology, we profiled changes in protein tyrosine
phosphorylation in vivo, across 50 mouse livers under different conditions of diet and
genotype. The scale of this study was crucial to developing the statistical power required to
gain confidence in phosphorylation trends, detect PTP1b-dependent pathways, and to
construct multivariate models of lipid metabolic phenotypes as functions of the underlying
molecular network.
Our results establish new roles for PTP1b deficiency in modulating hepatic lipid
metabolism. Multiple phosphorylation sites on proteins involved in lipid metabolism are
significantly affected by PTP1b deletion, and comprehensive lipidomics analysis
demonstrated that L-PTP1b−/− mice have several previously unappreciated metabolic
abnormalities. For instance, although total levels of FAs are similar between L-PTP1b−/−
and control mice on HFD, L-PTP1b−/− mice have an overabundance of longer-chain
PUFAs, including ω7/ω9 PUFAs and select ω3/ω6 species. Unfortunately, the physiological
roles of most of the PTP1b-dependent PUFAs are not well characterized. However, when
HFD and NC FA measurements are clustered, PTP1b-dependent ω3/ω6 species cluster with
DHA and EPA, suggesting anti-lipogenic and/or anti-inflammatory roles for these species.
The multivariate regression models suggest multiple mechanisms by which altered tyrosine
phosphorylation levels might lead to altered PUFA profiles in the L-PTP1b−/− mice
(Figures 7A and 8). The ω7+ω9 and ω3+ω6 PTP1b-dependent PUFA clusters have several
predictive phosphosites in common (Figure 7A). These PUFA share several biosynthetic and
metabolic pathways; thus, common sites are likely to contribute to processes governing both
sets of lipids. CYP2E1 Y426, ACLY Y672, enolase 1 (ENO1) Y25, glutamine synthase
(GLUL) Y336, and keratin 8 (K8) Y210 strongly contribute to both models. Although all of
these sites have unknown function, we have attempted to infer functionality from the
characterized role of the protein. For instance, CYP2E1 has stereospecific hydroxylase and
epoxidase activity for PUFAs. CYP2E1 Y426 is hyperphosphorylated when PTP1b is
deleted, and, were this site inhibitory, decreased CYP2E1 PUFA metabolism might
contribute to the increased levels of both ω3/ω6 and ω7/ω9 PUFA. ACLY converts cytosolic
citrate to acetyl-CoA and represents a potential control point in lipid metabolism. ACLY
protein and activity were elevated in livers of db/db mice, and shRNA depletion of ACLY
dramatically improved steatosis through repression of PPARγ and other lipogenic genes34.
Given that the expression of lipogenic genes was decreased in two previous studies of L-
PTP1b−/− mice8, 9 and that ACLY pY782 is hyperphosphorylated in these livers, this site
could be inhibitory. However, ACLY can directly affect the levels of acetyl-CoA and
protein acetylation35, and therefore we cannot rule out a pleiotropic effect, whereby altered
acetylation of multiple enzymes might influence both ω3/ω6 and ω7/ω9 PUFA.
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Additional phosphorylation sites in the ω7/ω9 PUFA model are implicated in lipid
metabolism. For example, CYB5 is an electron-transporting heme protein of the ER that co-
localizes with Δ5, Δ6, and Δ9 desaturases36, 37. These enzymes, in coordination with
elongases, are required for the biosynthesis of long-chain PUFAs38. CYB5 is necessary for
SCD function and it promotes Δ6 (FADS2) desaturase activity39. Because both SCD index
and CYB5 Y11 phosphorylation are elevated in L-PTP1b−/− livers, increased
phosphorylation of CYB5 Y11 may potentiate SCD activity, either via direct effects on
enzymatic activity or via altered protein-protein interactions in CYB5 complexes.
Additionally, CYB5 contributes to PUFA metabolism via interaction with cytochrome
P450s, including CYP2E1. It is possible that the altered phosphorylation of CYB5 Y11
modifies multiple aspects of lipid metabolism simultaneously.
Other PTP1b-dependent phosphosites might contribute to an excess of PUFA via defects in
pathways leading to TG and/or complex lipid formation. ACBP, which binds acyl-CoA
esters (C14–C22) with high specificity and affinity (Kd<.5nM)40, 41, is
hyperphosphorylated on pY29 in L-PTP1b−/− mice (Figure 1B). The crystal structure for
ACBP is available, and Y29 stabilizes the 3′ ribose phosphate of the acyl-CoA42.
Phosphorylation of Y29 would electrostatically repel the 3′ ribose phosphate, potentially
destabilizing the binding of acyl-CoAs to pY29-ACBP. If pY29-ACBP has compromised
acyl-CoA binding, free PUFA in PTP1b-deletion livers might abound due to (1) impaired
transport of acyl-CoAs to cellular sites of complex lipid synthesis and (2) a build-up of
untransported acyl-CoAs, which would inhibit PUFA activation to acyl-CoAs by long-chain
acyl-CoA synthetases. This mechanism would also be consistent with the compositional
depletion of long-chain PUFA-rich TGs in L-PTP1b−/− livers and serum. PTP1b-dependent
phosphorylation of PRDX6 (Y89), a bifunctional protein with glutathione peroxidase and
phospholipase A2 activities43, was also detected. A pY89-dependent increase in
phospholipase activity could also contribute to the PTP1b-dependent PUFA accumulation.
Given the diverse roles of proteins with altered tyrosine phosphorylation, it is likely that
altered PUFA composition in the L-PTP1b−/− livers is due to multiple mechanisms,
including increased desaturase activity (CYB5 Y11), decreased PUFA metabolism
(CYP2E1 Y426), increased lipase activity (PRDX6 Y89) and modulation of pathways
leading to complex lipid synthesis (ACBP Y29, ACSL5 Y69 and SND1 Y908) (Figure 8).
L-PTP1b −/− livers are ~2-fold more steatotic than controls on HFD, yet elevation of liver
TGs did not correlate with markers of inflammation, suggesting that the steatosis was not
associated with compromised liver function. Comparison of total liver and serum TGs in L-
PTP1b−/− mice indicates defective TG secretion, which could contribute substantially to
steatosis. In addition, MS-based analysis of TGs revealed MUFA-enriched compositions in
both the liver and serum of L-PTP1b−/− mice on HFD, suggesting that any hepatic TG
secretion defect was general (i.e., not specific to MUFA-rich or PUFA-rich TGs). Previous
measurements of lipogenic gene expression and the pS79 ACC ratio provide no evidence for
enhanced lipogenesis in L-PTP1b−/− mice; thus, the elevation in MUFA-rich TGs is most
likely attributable to diet-derived, as opposed to de-novo synthesized, FAs (discussed in
Results). Increased storage of diet-derived SFAs as TGs could be mediated by increased
SCD activity, as evidence suggests that SCD colocalizes with and funnels newly synthesized
MUFA products to diacyl glycerol acyl transferase 2 (DGAT2), a DGAT isoform that
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targets TGs to cytosolic storage rather than VLDL secretion44. Thus, elevated SCD activity
could contribute to the MUFA-rich TG composition in L-PTP1b−/− mice. In addition,
elevated SCD activity might mitigate HFD-induced inflammation via conversion of diet-
derived saturated FAs (SFAs) to MUFAs and funneling of MUFAs to TGs via DGAT2, as
MUFAs are typically less cytotoxic than SFAs and TGs are inert45, 46 (Figure 8).
Elevated PUFAs could contribute to defective TG secretion in L-PTP1b−/− mice. ω3 PUFA
not only decrease hepatic TG output via suppression of lipogenesis but also independently
inhibit TG secretion47. DHA inhibition of TG secretion is mediated by lipid peroxidation
followed by the degradation of apolipoprotein B (ApoB), the central component of VLDL
particles, which was specifically sensitive to the PUFA-mediated oxidative damage32. In
this same study, several other dietary PUFAs, including linoleic acid (C18:3 ω3) and
arachidonic acid (C20:4 ω6), were shown to promote ApoB degradation via peroxidation.
Lipid peroxide formation was positively correlated with polyunsaturation of FAs,
independent of the double bond position. In the current study, we suspect that PTP1b-
dependent increase in PUFA might inhibit VLDL secretion by lipid peroxidation and
oxidative degradation of ApoB, potentially through altered activity of REDOX proteins
whose phosphorylation patterns were predictive in the steatosis model (Figures 7A, 8, Table
S11). This mechanism would also be consistent with observations from a previous study, in
which pulse-chase analysis of ApoB100 in primary hepatocytes from whole-body PTP1b
knockout mice demonstrated reduced secretion of ApoB100, and insulin-stimulated HepG2
cells overexpressing PTP1b had a decreased ApoB100 degradation rate48. Thus, it is likely
that enhanced ApoB degradation contributes to the secretion defect in L-PTP1b−/− mice,
potentially via altered REDOX regulation and PUFA peroxidation.
Our study also demonstrates the utility of computational approaches to gain biological
insights from complex multivariate datasets. First, we adapted GSEA15 for the discovery of
PTP1b-dependent pathways from the phosphotyrosine measurements. Using this approach,
we recovered known PTP1b-dependent pathways (insulin signaling) and discovered novel
PTP1b-dependent pathways: redox homeostasis, amino acid metabolism, and lipid
metabolism (particular FA metabolism). We evaluated several new ideas for multivariate
modeling of phenotypic response data from underlying molecular measurements. We
developed stochastic multivariate regression (SMR) to incorporate site-specific
measurement error into the model-building procedure. This method biases selection of
predictors toward higher quality measurements and offers a promising strategy to account
for variable levels of measurement noise across largescale datasets. Two important
considerations could improve SMR performance. First, optimization of measurement error
models could improve results. Here, when available, the standard deviation from technical
replicates was used (and, when unavailable, the dataset average standard deviation was used
to estimate error, see Methods). However, as error itself is randomly distributed, this method
may unfairly increase the weight or importance of measurements with randomly small
standard deviations and, similarly but less worrisome, limit the influence of measurements
with randomly large standard deviations. A second future direction would be to weight the
final fit of the SMR model. Measurement error is currently incorporated into the variable-
selection procedure, as it influences the significance ranking of coefficients, and, therefore
indirectly biases model fit toward higher confidence predictor and response measurements.
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The model fit in the SMR procedure, however, is unweighted, linear least squares, which
does not incorporate measurement error. As highlighted in Figure 7B, individual response
measurements have a spread of associated measurement error, and model predictive
performance might benefit from a weighted-fit approach (e.g., inverse error).
Additionally, we evaluated methods to deal with systematically missing data points, a
common feature of MS-based proteomic datasets, and applied set-enrichment analysis to
gain additional, pathway-level insight into the variables underlying model prediction. The
resulting multivariate analyses lead to models that predict lipid metabolic phenotypes as
functions of underlying tyrosine phosphorylation sites, providing biological insights in a
quantitative and unbiased way.
Although we have focused mainly on PTP1b-dependent phosphorylation of proteins
involved in lipid metabolism, PTP1b-dependent phosphosites are present on a much larger
set of proteins. There is much to be learned about the roles that these phosphorylation sites
might play in the context of metabolic syndrome. It is our hope that this study will stimulate
further research of the diverse pathways and surprising phenotypes modulated by PTP1b
inhibition.
Materials and Methods
Animal Studies
L-PTP1b−/− mice were generated as described8. Genotyping for the PTP1b floxed allele and
the presence of Cre was performed by PCR. Hepatic PTP1b protein expression was assessed
at the end of the study by quantitative immunoblotting (PTP1b antibody AF13661, R&D
Systems). Mice were maintained on a 12-hour light/dark cycle in a temperature-controlled
barrier facility with free access to water and food. Diets consisted of Prolab 5P76 Isopro
3000 (NC) and Teklad TD.93075 (HFD). For tissue harvesting, mice were fasted overnight,
anesthesized with an i.p.-injection of 150mg/kg pentobarbital sodium (Nembutal Lundbeck,
Inc), and, when judged unconscious (~2min), the abdominal cavity was opened and livers
were snap-frozen and extracted using liquid-nitrogen-chilled freeze clamps. For insulin
stimulation, 10mU/g insulin (Novo Nordisk Novolin R) was i.p.-injected 10min. prior to
harvesting. Tissues were stored for subsequent biochemical analyses at −80°C. Mouse
procedures were performed in accordance with the guidelines and approval of the
institutional animal care and use committees at the University of Massachusetts Medical
School and the Ontario Cancer Institute.
Serum measurements
At 5.5 and 6.5 weeks of NC or HFD, fed and fasted serum samples were collected from the
tail veins of mice. Adiponectin, glucagon, cholesterol (total, HDL, and LDL) were measured
in the fasting serum samples. Insulin and glucose were measured in both fasted and fed
serum samples. Serum hormones (insulin, glucagon, leptin, adiponectin) were measured
using reagents purchased from Millipore and run on a Bio-Plex 200 System; hormone levels
were determined by a logistic 5pl standard curve fit. Lipid analysis was performed on a
Roche Cobas c111 chemistry analyzer. Glucose was measured using an Analox glucometer.
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Phosphotyrosine analysis
Peptide sample processing—In a 4°C room, aliquots of frozen liver, at an estimated
mass ~100mg, were placed in 5mL round-bottom polypropylene tubes containing 3mL ice-
cold 8M urea and immediately homogenized using a Polytron homogenizer. Protein
concentration was estimated by bicinchoninic acid (BCA) assay (Pierce). Sample proteins
were reduced (1hr, 10mM, DTT, RT), alkylated (1hr, 55mM iodacetamide, 56C), and
digested (1:50 protein to modified trypsin (Promega) ratio, in ammonium acetate buffer, pH
8.9, which was added to original tissue lysate such that urea concentration in the final
solution was reduced to 800mM; reaction ran on a rotor for 20 hrs. at RT and was stopped
by addition of 1mL acetic acid (99.99%)). The digests were centrifuged, and supernatants
were desalted and fractionated on C18 Sep-Pak Plus cartridges (Waters). Peptides that eluted
with 25% acetonitrile in 0.1% acetic acid were lyophilized. Peptide sample aliquots
(corresponding to 800ug of starting protein) were labeled with 8-plex iTRAQ (2 aliquots of
label per peptide sample). Sets of eight distinctly labeled peptide samples were combined.
For both insulin-stimulated and basal conditions, one liver sample was selected as a control
and included in all insulin-stimulated or basal experiments to enable quantification across
experiments.
Enrichment of phosphotyrosine peptides—A phosphotyrosine peptide IP was
performed, as described13, with slight modification to the anti-phosphotyrosine antibodies
used. Here, antibodies included 12ug 4G10 (Millipore), 12ug PY100 (CST), and 12ug PT66
(Sigma), with 60uL protein G agarose beads (Calbiochem). Peptides were eluted from the
antibodies with 70uL 100mM glycine, pH 2.1. To address non-specific binding from the
phosphotyrosine peptide IP, an immobilized metal affinity chromatography step (IMAC)
was used for further enrichment of phosphopeptides13. Phosphopeptides were eluted from
the IMAC column to a capillary precolumn.
LC-MS/MS—The capillary precolumn (100um i.d., packed with 10cm of ODS-A, 12nm,
S-10um beads (YMC)) was connected to a capillary analytical column (50um i.d., packed
with 10cm of ODS-AQ, 12nm, S-5 μm beads (YMC), with a laser-pulled (Model P-200;
Sutter Instrument) electrospray ionization emitter tip (<1um diameter))49. Peptides were
eluted from the liquid chromatography column (flow rate ~ 20nL/min) to an LTQ Orbitrap
XL mass spectrometer (Thermo Fisher Scientific) with the following gradient: 0min: 0% B;
10min: 13% B; 105min: 42% B; 115min: 60% B; 122min: 100% B (solvent A = .2 mM
acetic acid and solvent B = 70% acetonitrile, 2mM acetic acid). Data were collected using a
data-dependent acquisition mode: a high resolution MS1 scan on the Orbitrap was followed
by up to 10 pairs of data-dependent MS/MS scans of the most abundant MS1 precursor ions.
Each MS/MS pair consisted of one MS/MS scan on the LTQ (isolation width 3m/z, CID
fragmentation, 35% collision energy) and a second MS/MS scan on the Orbitrap (isolation
width 3m/z, HCD fragmentation, 75% collision energy). The Orbitrap MS/MS provided
high-resolution iTRAQ quantification, while the LTQ MS/MS scan provided better
sequence information. Dynamic exclusion for the data-dependent scans was set to 120sec.
MS Data processing—Xcaliber (.raw) data files were converted to MASCOT generic
format (.mgf) with DTASuperCharge (version 1.19) and searched with MASCOT v2.1
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(Matrix Science) against the National Center for Biotechnology Information (NCBI) mouse
proteome with a peptide tolerance of 10ppm, MS/MS tolerance of .8 Dalton, 1 missed
cleavage, fixed modifications (methyl-cysteine and 8-plex iTRAQ), and variable
modifications (methionine oxidation, tyrosine phosphorylation, and serine/threonine
phosphorylation). Mascot peptide identifications, phosphorylation site assignments and
quantification were verified manually. Phosphorylation site assignments were made using
PTMScout50.
Relative quantification of phosphotyrosine peptides—Given the high resolution of
the Orbitrap, the peak heights of iTRAQ reporter ions were used to quantify the relative
amounts of phosphopeptides across an 8-plex experiment. Peak heights in a spectrum were
normalized to mean iTRAQ peak intensity. If multiple, validated spectra existed for the
same phosphosite, these spectra were averaged. For normalization of phosphorylation
measurements, 0.2% of the supernatant from the phosphotyrosine-peptide IP was also
analyzed by LC-MS/MS. This provided quantitative information for the most abundant
(unphosphorylated) peptides in the sample, which were assumed, on average, to be constant
across all samples (with the exception of blood proteins like hemoglobin and blood serum
albumin, which were excluded from the analysis). The supernatant iTRAQ peak heights
were normalized relative to the mean iTRAQ peak height for each spectrum, resulting in
~1000, 8-dimensional peptide ratios. The median of the 90% least-outlying peptide ratios
(outlying by multivariate T2 statistic) was used as a normalization factor for the
phosphopeptide quantification. After relative quantification was achieved within each
individual phosphotyrosine analysis, relative quantification across analyses was
accomplished by normalizing each individual analysis to the control livers. Associated error
was determined by calculating the relative standard deviation for samples run multiple times
but in separate phosphotyrosine peptide quantification experiments. The mean absolute and
relative standard deviations were 0.10 +/− 0.10 and 10% +/− 10%, respectively.
Principal component analysis and variance explained by diet and genotype
Principal component analyses51 were used to decompose the insulin-stimulated (insulin) and
basal phosphotyrosine data matrices separately. For a data matrix, X [N samples by M
phosphosite measurements], the contributions of all sites to each of the principal
components is preserved in the loadings matrix, P, and the position of each of the samples in
principal component space is contained in the scores matrix, T. The relationship among P, T,
and the corresponding data matrix, X, is:
(S1)
where the dimensions of T, and P are [N × p] and [M × p] and N, M, p are the number of
liver samples, number of phosphosite measurements, and the number of principal
components used, respectively. (PT is the transpose of P.)
PCA requires that the data matrix be complete. Given the systematically missing data points
in the phosphotyrosine datasets that resulted from merging of multiple data-dependently
acquired MS/MS experiments, techniques for imputing or estimating missing data were
necessary for application of PCA. Analysis was limited to phosphorylation sites that had
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data for at least 70% of the samples in the insulin or basal datasets, and data were mean-
normalized. Multiple random imputation52 was used to deal with the remaining missing data
points. For each phosphosite measurement (column of X) with missing data points, a sample
was randomly selected from those present to replace missing values. This procedure was
repeated for each phosphosite with missing sample measurements, and the resulting,
complete matrix, XC, was used to estimate T and P. This random imputation procedure was
repeated 1000 times, and results were averaged to yield matrices Tave and Pave. The columns
of Tave and Pave were then made orthogonal and orthonormal, respectively, using the
Gramm-Schmidt process.
The variance explained by factors (diet, genotype) was estimated as follows:
(S2)
where M is the total number of phosphosites in the dataset, phosij is the phosphorylation
level for the ith phosphosite in the jth sample, j ={1,.2,…N}, phosi,mean is the mean for the ith
phosphosite, and phosj,est(i) is the estimate of phosij resulting from regression of the ith
phosphosite phosphorylation levels onto a corresponding indicator vector of factors
(genotype or diet). Note that complete data are not required for this calculation, as phosj,est(i)
is calculated independently for each phosphosite, using only the data points for the ith
phosphosite that are present. These and all subsequent computational and statistical analyses
were performed in Matlab Version 7.10.0.499 (R2010a).
Heatmaps of genotype- and diet-dependent phosphorylation sites
To visualize genotype- or diet-dependent phosphosites in both global and condition-specific
contexts, we used the following procedure. For detection of genotype-dependent
phosphosites, we estimated the Pearson correlation coefficient and p-value for each
genotype-phosphosite pair across the following, independent data subsets: HFD/basal, NC/
basal, HFD/insulin, and NC/insulin. Then, p-values for each genotype-phosphosite pair were
combined, using Fisher’s method, to create p-values for each of the following situations:
PTP1b dependence across all datasets, NC-only PTP1b dependence, HFD-only PTP1b
dependence, PTP1b dependence under insulin-stimulation only, PTP1b dependence under
basal conditions only, and HFD/basal, NC/basal, HFD/insulin or NC/insulin conditions only.
For example, to calculate a p-value for the “PTP1b-dependent under insulin-stimulation
only” context, Fisher’s method was used to combine p-values from HFD/insulin and NC/
insulin correlations. Phosphosites with at least one context-specific, raw P-value < .025 were
included in Figure 2B heatmap. Similarly, for diet-dependent phosphosites, correlation
coefficients and p-values were calculated for the following, independent data subsets: basal/
PTP1b−/−, basal/control, insulin/PTP1b−/− and insulin/control, and context-specific p-values
were estimated analogously to the genotype case. Phosphosites with at least one context-
specific, raw P-value cutoff of .025 were included in Figure S1 heatmap.
Miraldi et al. Page 19
Integr Biol (Camb). Author manuscript; available in PMC 2014 July 24.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Phosphosite-Set Enrichment Analysis
PSEA directly follows from the GSEA protocol for multiple set-enrichment tests, described
in15. Genotype and diet analyses incorporated all phosphotyrosine datasets, and sites were
ranked according to significance of correlation with genotype or diet. In particular, the
significance and direction of correlation of genotype with a phosphosite was calculated, if
possible, for the four relevant, independent data subdivisions (HFD basal, HFD insulin, NC
basal, and NC insulin), then the independent p-values were combined using Fisher’s method
and accounting for the direction of the correlation. Diet-dependence was analyzed
analogously, and the independent data subsets were L-PTP1b−/− + insulin, control + insulin,
basal L-PTP1b−/−, and basal control. For these analyses, phosphosites were ranked
according to the overall direction of correlation coefficient multiplied by the log10-
transformed p-value.
Phosphosite sets (Table S3) were tested for enrichment. For each analysis, only those sets
with five phosphosites or more were tested. Thus, given incomplete data, the genotype and
diet analyses tested 59 and 45 sets, respectively, while 56 sets were tested for relevance to
phenotype prediction using SMR models. For each set, normalized enrichment scores
(NESs) and significance were calculated as in15. Random NES distributions were generated
by calculating set NESs from 500 lists of sites ranked according to significance of
correlation to randomly permuted genotype or diet vectors. Raw p-values for enrichment
among diet- and genotype-dependent sets were derived from corresponding random NES
distributions, and Benjamini-Hochberg corrections was used to estimate false-discover rate
(FDR) and control for multiple-hypothesis testing.
Note, PSEA yielded numerous PTP1b-dependent sets but only a single, significantly diet-
dependent set. This is due to experimental design. Each MS 8-plex iTRAQ experiment was
optimized for comparison of L-PTP1b−/− mice to control, rather than for comparison of
HFD to NC mice. As a result, whereas every MS experiment enabled genotype comparison,
diet comparison was accomplished by pooling the overlapping sites from multiple runs.
Thus, fewer samples were available for the diet comparison, and we lacked statistical power
equivalent to the genotype-dependent case. If additional MS experiments were run for diet
comparison, additional diet-dependent phosphotyrosine sets would likely be uncovered.
The stochastic multivariate regression (SMR) method described below was used to generate
ranked lists of sites relevant to SMR prediction of steatosis, ω3/ ω6 PTP1b-dependent
PUFA, and ω7/ ω9 PTP1b-dependent PUFA for analyses. Sites were ranked according the
sign of the regression coefficient multiplied by the −log10-transformed p-value associated
with the coefficient. This analysis was limited to the HFD basal data subset only.
Lipidomics analysis
Lipid extraction—In a 4°C room, aliquots of frozen liver tissues were weighed (~120mg
per tissue sample) and placed on dry ice. Lipids were extracted in 6mL of a 2:1:1 solution of
CHCl3: MeOH: H2O. To quantify the absolute abundances of select lipids, reference
standards were spiked into the chloroform phase (670nmol (HFD) or 330nmol (NC) glyceryl
triheptadecanoate (Sigma), 1.5μmol (HFD) or 750nmol (NC)
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Cholesterol-25,26,26,26,27,27,27-d7 (C/D/N Isotopes), 5nmol UC13-oleic acid (Spectra
Stable Isotopes), 500pmol UC13-palmitic acid (Spectra Stable Isotopes), 50pmol arachidonic
acid-5,6,8,9,11,12,14,15-d8 (Cayman Chemical), and 5pmol eicosapentaenoic acid-19,19′,
20,20,20-d5 (Cayman Chemical)). Frozen tissues were placed into a 15-mL dounce tissue
grinder and homogenized in the extraction solution on ice. The extract was transferred to a
glass vial and centrifuged at 2,500G, 4°C for 5min to separate the organic and aqueous
layers. The organic layer was transferred to fresh glass vials twice by Pasteur pipette. The
final glass vial was placed under a stream of nitrogen until the organic phase evaporated.
Samples were stored at −80°C and later dissolved in chloroform for LC-MS analysis53.
LC-MS analysis—LC-MS analysis was performed using an Agilent 6220 LC-ESI-TOF
instrument. For LC analysis in negative ion mode, a Gemini (Phenomenex) C18 column
(5um, 4.6mm × 50mm) was used in combination with a precolumn (C18, 3.5um, 2mm ×
20mm). Mobile phases A and B were 95:5 water:methanol and 60:35:5
isopropanol:methanol:water, respectively; both contained 0.1% ammonium hydroxide. For
positive-mode LC analysis, a Luna (Phenomenex) C5 column (5um, 4.6mm × 50mm) was
used with a precolumn (C4, 3.5um, 2mm × 20mm). Mobile phase A and B had the same
solvent compositions as negative mode, except, A and B were both supplemented with .1%
formic acid and 5mM ammonium formate instead of 0.1% ammonium hydroxide. For both
analysis modes, a 60min gradient was used: 100% A, flow rate .1mL/min from 0–5min, a
linear increase in solvent B from 20% to 100% at .4mL/min from 5–45min, isocratic 100%
solvent B for 7min at 0.4mL/min, and equilibration with 100% solvent A at 0.5mL/min for
8min53.
For preliminary, discovery-motivated experiments, 16% of the sample was run in a 30uL
injection volume for both modes. In quantitative, follow-up positive mode analyses focusing
on triglycerides, 1/240th (HFD) or 1/80th (NC) of the sample extract was injected in 30uL. In
quantitative, follow-up negative mode analyses focusing on fatty acids, two analyses were
required, because fatty acid abundances span more than four orders of magnitude. In the first
analysis, to avoid saturation of the most abundant fatty acids (oleic, stearic and palmitic),
sample amount was limited to 1/80th–1/240th of the extract, and a 15uL injection volume
was used. In addition, the LC lines were typically coated with a significant background of
palmitic and stearic acid, so the lines of the LC were purged overnight with a 1% acetic acid
DMSO solution to ensure that background from stearic and palmitic acids was < 20% of
sample signal the next day. For the second analysis and to better separate isomers of low
abundant fatty acids, 1/6th of the sample extract was injected using a 5uL volume and an
80min gradient was developed: 0–5min 100% A at 0.1mL/min, linear increase in solvent B
from 20% to 40% from 5–15min at 0.4mL/min, (slower) linear increase in solvent B from
40% to 80% from 15–55min at 0.4mL/min, linear increase in solvent B from 80% to 100%
from 55–65 at 0.4mL/min, isocratic 100% B from 65–73min at 0.4mL/min and, finally, a
7min equilibration step with 100% A at 0.5mL/min.
MS analysis was performed with an electrospray ionization (ESI) source. The capillary
voltage was set at 4kV and the fragmentor voltage to 100 V. The drying gas temperature was
350C, at a flow rate of 10L/min. The nebulizer pressure was 45psi. Data were collected in
both centroid and profile modes with a mass range of 100–1500Da.
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Automated discovery of differential metabolites—XCMS54 was used to match,
quantify, and compare peaks across an initial, exploratory lipidomics analysis of six L-
PTP1b−/− mice and seven control mouse livers under HFD, basal (HFDB) conditions.
Agilent chromatogram data files (.d) for both positive and negative mode 60min-gradient
analyses were obtained from Agilent MassHunter and converted to mzXML files by the
software program Trapper. The mzXML files were analyzed by XCMS using the default
parameters. The final output file contained ion m/z ratio, average retention time, integrated
mass ion intensities (peak area), and a p-value corresponding to a t test to determine whether
the ion was differentially abundant between L-PTP1b−/− and control mice. Ions that XCMS
indicated might be differentially abundant were then examined individually for verification
by hand.
Absolute quantification of hepatic triglycerides and cholesterol—Detectable
hepatic triglyceride species ranged from total acyl change carbon length of 48 to 56. Manual
integration of ion chromatograms (20 ppm m/z window) was performed, so that only ion
chromatogram area corresponding to the monoisotopic peak of the triglyceride was included
in the integration. In addition, triglyceride peak areas from sample analyses were compared
to background from blanks, and several triglycerides were excluded from the dataset (i.e.,
C48:0, C50:0), as background was >20% of the signal. Integrated peak areas were then (1)
normalized to the peak area of the glyceryl triheptadecanoate standard and (2) normalized to
the starting tissue mass to obtain absolute quantification (in nmol triglyceride / mg tissue).
Total triglyceride amount was obtained by summing all triglyceride species quantified.
Percent triglyceride composition was calculated by dividing each triglyceride structural
isomer by total triglycerides. For liver tissue samples with replicate analyses, these
replicates were combined using the principal component alignment method described below.
Absolute cholesterol quantification was obtained by normalizing to the cholesterol-d7
standard and starting tissue masses.
Absolute quantification of hepatic fatty acids—LC-MS data were inspected
manually and ion chromatograms were integrated with 20ppm m/z tolerance, as above. As
described above, two separate MS runs were required for quantification of high abundance
and low abundance species, so that the former did not saturate the detector and the latter
were detectable. The original plan for combining quantification of low and high abundance
runs for single sample was to quantify each run independently: construct standard curves
from the four fatty acid standards (spiked into samples before processing and spanning four
orders of magnitude), quantify the fatty acids using the run-specific standard curve, and
average fatty acids that were quantified in both high-abundance and low-abundance runs.
However, for the analyses of highly abundant fatty acids, which were limited to small
sample amounts, often only two standards were detected. As one might expect, the standard
curves (in log-log space) were very sensitive to noise in the measurement of those standards.
Similarly, the most abundant fatty acid standard often saturated in analysis of the low-
abundance fatty acids, resulting in a calibration curve of three points, which was also very
sensitive to measurement noise.
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To overcome these issues, we devised a new method for integrating the high and low
abundance datasets. Rather than limit calibration curve-fitting to the four or fewer standard
fatty acids detected per run, our method incorporates all fatty acids common to high- and
low-abundance runs (> 10 fatty acid pairs) into each sample calibration. Principal
component analysis is used to find one principal component (fit a line) from the paired peak
areas from high and low abundance analyses. The fatty acids not common to both runs are
then projected onto the first principal component, so that all of the fatty acids have positions
on the principal component. The positions of the standards are used to determine the linear
relationship between principal component position and absolute units of quantification
(pmol). We found that this approach was more robust to noise in standard measurements,
because it made use of more data points and resulted in a global fit. In addition, often there
were more than two MS analyses per sample, and this method of principal component
alignment was easily extended to enable global alignment of multiple runs.
After calibration to standards, fatty acid abundances were normalized to starting tissue mass
to obtain absolute quantification (pmol fatty acid / mg tissue). Percent composition was
obtained by dividing each fatty acid by the sum total of all fatty acid abundances.
Identification of selected fatty acid isomers by co-injection—C18:3 ω3, C18:3
ω6, 18:3 ω9, C20:3 ω3, C20:3 ω6, C20:3 ω9, C22:3 ω3 standards were purchased from
Cayman Chemicals, while C24:6 ω3 was purchased from Laradan Fine Chemicals AB. The
LC-MS protocol used for all co-injection experiments was the same as described for analysis
of low abundance fatty acids above. For each fatty acid species, the following runs were
performed: each standard was run individually (10pmol), all isomers of that species were
run together (10pmol each), an HFD liver tissue sample was run individually (1/6 sample),
and finally 1/6 sample of HFD liver tissue was co-injected with isomer standards, whose
concentrations were titrated so that the co-elution of standard with particular endogenous
peaks could be identified.
For C18:3, two sets of standard concentrations were used in the co-injection experiments to
identify the 3rd isomer peak: (1) 1.25pmol C18:3 ω3, C18:3 ω6, and C18:3 ω9 and (2)
2.5pmol C18:3 ω3 and C18:3 ω6 with 6.25pmol C18:3 ω9 (Figure S2A, red and purple
lines, respectively). None of the standards co-eluted with the PTP1b-dependent isomer peak.
Because (1) isomer standards elution times increased with ω-bond distance (i.e., eluted in
the order ω3, ω6, ω9), and (2) the endogenous peak of interest eluted in between the ω6 and
ω9 peaks, we suspect that the endogenous peak corresponds to C18:3 ω7. Because we did
not have a standard to confirm this assignment, this peak is referred to as C18:3 ω7* in the
text.
For C20:3, two sets of standard concentrations were used in the co-injection experiments to
identify the 2nd isomer peak: (1) 500fmol C20:3 ω3 and C20:3 ω6 with 3.4pmol C20:3 ω9
and (2) 1pmol C20:3 ω3 and C20:3 ω6 with 3.4pmol C20:3 ω9 (Figure S2B). C20:3 ω3 and
ω6 co-eluted with the first peak, while C20:3 ω9 co-eluted with the second peak. In the
absence of an ω7 C20:3 standard, we concluded that the most significantly differential peak
is either ω9, ω7, or a combination of both isomers, and we therefore refer to this peak as
C20:3 ω9/ω7*.
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For C22:3, 150fmol and 450fmol C22:3 ω3 were run with endogenous lipid sample in two
separate runs (Figure S2C). C22:3 ω3 co-eluted with the first (less significantly PTP1b-
dependent) of the two C22:3 isomer peaks. Given the similarity between the profiles of
C20:3 and C22:3 (two distinct isomer peaks) and that, in the reverse-phase chromatography
used, isomer separation decreases with increasing carbon chain length, we suspect that
C22:3 ω6 would co-elute with C22:3 ω3, as was the case for C20:3 ω3 and ω6, and that the
second peak, similar to the second peak of C20:3, corresponds to ω7 and/or ω9 species.
Thus, we refer to the PTP1b-dependent C22:3 peak as ω7*/ω9*.
For C24:6, co-injection runs with 50fmol and 300fmol C24:6 ω3 were performed (Figure
S2D). The single C24:6 peak co-eluted with a C24:6 ω3 standard, confirming its
identification as a C24:6 fatty acid structural isomer. Even though isomer separation
decreases with increasing carbon chain length, we can conclude that the isomer peak is not
ω7/ ω9 because double bonds on fatty acids must be separated by at least one unsaturated
carbon, and thus the only other feasible placement of the ω bond would be at the ω6
position. Here, we denote the peak as C24:6 ω3/ ω6*.
Estimation of technical error—The technical error associated with the quantification of
hepatic lipids was estimated via analysis of technical replicates. Here, technical replicates
are separate samples from one mouse liver tissue that were processed, run, and quantified on
different days. There were five such technical replicates for fatty acid analysis. The percent
error associated with absolute fatty acid abundances was 17% +/− 15% (mean +/− standard
deviation), while the percent error associated with percent composition estimates was 19%
+/− 15%. For the triglyceride analysis, there were four technical replicates, and the percent
error associated with absolute triglyceride structural isomer abundances was 15% +/− 10%,
while the percent error associate with percent composition measurements was 22% +/−
10%. For both triglycerides and fatty acids, percent relative standard deviation was constant
with respect to lipid abundance.
Enzymatic assay of hepatic triglycerides—Triglycerides were quantified as
described8, using the Stanbio Triglyceride Liquicolor Test kit.
Serum triglyceride analysis—Serum triglyceride analysis was performed as
described25, with the following changes: a Jupiter C4 column (4.6 × 150mm, 5μm particle
size, 30nm pore size, Phenomenex) was used at a 700uL/min flow rate, and data were
acquired on an Agilent 6220 LC-ESI-TOF instrument.
Unsupervised clustering analysis of lipidomics datasets
Lipid measurements were scaled by z-scoring, and a correlation-based similarity matrix was
used as input to the affinity propagation clustering algorithm55. Measurements within AFP-
derived clusters were ordered using hierarchical clustering with correlation distance.
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Biochemical analysis
Cytokine markers of hepatic inflammation—Bio-Plex Pro Mouse Cytokine Sets were
used for quantification of hepatic IL-6, IL-1b, and MCP-1 content, using the Bio-Plex 200
System.
Immunoblot analysis—Antibodies for pS79 ACC, ACC, pT172 AMPK, AMPK, pT180
and pY182 p38, and β-actin were purchased from Cell Signaling Technology.
Stochastic Multivariate Regression
Stochastic multivariate regression (SMR) employs Gaussian sampling of the data (by
sampling from distributions derived from experimental technical replicates) and
bootstrapping techniques (where distinct samples are bootstrapped) to construct distributions
of regression coefficients connecting phosphosites to phenotypic measurements. Required
algorithm inputs include an independent variable matrix (e.g., of phosphosite
measurements), X [N×M] and Xstd [N×M], corresponding to N samples and M measured
variables, and a dependent variable matrix (e.g., of lipid measurements), Y [N × V] and Ystd
[N x V], where V is the number of dependent variables measured. The matrices X and Y
correspond to measurement means, while Xstd and Ystd contain measurement standard
deviation. In the absence of a technical replicate for a given measurement, the standard
deviation was estimated using the average relative standard deviation of the corresponding
dataset.
If X corresponds to an MS-based phosphosite dataset, then X is likely to have dimensions
such that M > N. While there are several multivariate regression algorithms that work in this
regime and SMR could be implemented using any of them, partial least squares regression
(PLSR) was selected here, mainly because its execution is fast in Matlab. Building of a
PLSR model involves the simultaneous decomposition of both X and Y matrices into X and
Y scores and loading matrices. Assuming X and Y are mean-centered, the key PLSR matrix
relationships are described by the following equations:
(S3)
(S4)
where the X and Y scores matrices, T [N × pcs] and U [N × pcs], are optimized to co-vary
maximally; pcs is the number of model principle components, and P [M × pcs], C [P × pcs],
W [M × pcs], and B [M × P] are the X loadings, Y loadings, X weights, and regression
coefficient matrices, respectively56. The decomposition of X and Y determines the location
of a PLSR principle component plane. This plane is optimized to contain linear
combinations of independent variables that covary maximally with the dependent
variable(s), and, for this reason, this algorithm tends to perform well in a variety of
contexts57.
The basic SMR algorithm is as follows:
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1. Gaussian sampling for measurement noise. For each data point present in X, draw a
random sample, Xgaus(n,m) from a Gaussian distribution with mean, X(n,m), and
standard deviation, Xstd(n,m). Similarly, draw Ygaus(n,v), based on Y(n,v) and
Ystd(n,v), n = {1,2, …,N}, v = {1,2, …,V}. Recall that the N rows and and M
columns of X correspond to samples and variables, respectively. V corresponds to
the number of response variable measurements. Means and standard deviations of
X and Y are estimated as the sample mean and sample deviations measured across
technical replicates. If a data point does not have replicate measurements, its
standard deviation is estimated as the average sample deviation of the
corresponding data matrix.
2. X and Y Data normalization and averaging of Y matrix measurements. For each
column of Xgaus or Ygaus, mean-center the data and divide by the standard
deviation to yield matrices Xzscore and Yzscore. If V > 1, average Yzscore column-
wise to yield Yzscore,v [N × 1]. (Averaging Y simplifies subsequent model
reduction steps and does not change the modeling outcome so long as the response
measurements are related (non-orthogonal), as is the case for the response variables
considered here.)
3. Draw a bootstrap sample. Randomly select paired rows of Xzscore and Yzscore,v
without replacement and build Xboot and Yboot matrices, dimensions [N × M] and
[N × 1], respectively. In this way, measurement noise is modeled and accounted for
in Step 1, while bootstrapping at the level of distinct samples in Step 3 accounts for
biological sample variability.
4. Build the bootstrap regression model. Use PLSR, with number of principle
components equal to one minus the rank of Xboot, to estimation the linear
regression coefficients Bboot [M × 1].
5. Multiple imputation and Gaussian sampling. Repeat steps 1–4 until a user-
determined number, J, of bootstrapped models have been built. Store each model’s
vector of coefficients Bboot in the matrix Bmatrix [J × M].
6. Estimate the significance of each independent variable measurement to prediction.
For each measurement m in X, use the corresponding coefficient distribution
contained in column m of Bmatrix, to empirically test the null hypothesis that zero
belongs to this distribution.
7. Model reduction. Rank the independent variables according to coefficient
significance determined in 6. Sequentially build and evaluate PLSR models, by
varying (1) the number of principle components, pcs, in the model and (2) by
incorporating the top F ranked variables in the model. For this analysis, pcs = {1,
…,3}, and F = {1,2, …,20}.
R2 and Q2 statistics—Models were evaluated by estimating R2, goodness-of-fit, and Q4,
goodness-of-prediction, statistics:
Miraldi et al. Page 26
Integr Biol (Camb). Author manuscript; available in PMC 2014 July 24.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(S5)
(S6)
where Ymeas,n corresponds to the experimentally determined response measurement n,
Ymean is the average of the response measurements, Ypred,n is the model prediction for
response measurement n, Ypred,loocv(n) is the model prediction for response n, from a leave-
one-out-cross-validation (LOOCV) model, which excludes measurements for sample n, and,
similarly, Ymean,loocv(n) is the mean of the response measurements, excluding measurement
n. A Q4 value should estimate the variance explained by a model for an independent sample.
Typical Q4 calculations for PLSR involve (1) determination of a reduced set of independent
variables for model reduction using the full dataset and (2) fitting LOOCV models using that
pre-determined, reduced set of variables with LOOCV data subsets29, 31, 58. Such a protocol
inflates the Q4 value, because the left-out sample is not entirely independent of the LOOCV
model construction. Although the left-out sample is not involved in model fitting, it was
used for the variable selection step and, for the calculation of Q4 values in this analysis, the
model reduction procedure was included in the LOOCV modeling building. Thus, both
model reduction and model fit were determined based on the LOOCV data subset only, and
we found that this method results in lower Q4 values relative to the previously described Q4
estimation procedures, which account for model fit only.
Variation: Model reduction based on VIP-score—In addition, reduced models were
built by a second method, in which independent variables were ranked according to variable
importance of projection (VIP) score. The VIP score for a given independent variable and
PLSR model with pcs principle components is:
(S7)
where Varexp,Y(pc) is the variance in Y explained by regression onto a particular principle
component, pc, and W(m,pc) is the quantitative contribution that a particular measurement,
m, makes to the pcth PLSR principle component59. Because the PLSR principle component
plane is optimized to contain linear combinations of independent variable measurements that
covary maximally with the dependent variable, this metric performs well in model
reduction.
To implement SMR model reduction based on VIP score, it is necessary to estimate Varexp
and W from Equation S7, and we estimated these from the J X-loadings matrices, Pboot [M ×
pcs], that resulted from each bootstrap model-building process (see Step 5 and definition of
a loadings matrix, P, in Equation S5, above). Specifically, each of the Pboot matrices is
averaged to create an averaged X-loadings matrix, Pave [M × pcs]. Thus, by averaging,
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variable measurements that consistently contribute to the PLSR principle component plane
will have higher loading values and contribution to the model more than measurements
associated with larger amounts of error or that have missing values which must be randomly
imputed (see “Missing data techniques section” below). To make this loadings matrix
consistent with loadings matrix produced directly from PLSR algorithms, Pave is
orthonormalized row-wise. Pave is then used to derive W and Varexp,Y. The scores matrix, T
[N × pcs], are estimated by the equation T = XcPaveT and the weights, W, are estimated as
Pave/(PaveTPave). To derive Varexp,Y, the rows of T are orthogonalized, and, then the Y
loadings, C [pcs × 1] are calculated from C = (TTT)−1TTY*, where Y* is a vector average of
the z-scored Y matrix (similar to Yzscore,v in Step 2). Next, the Varexp,Y(pc), are calculated
using the equation: Varexp,Y(pc) = 1−(Y*−T(pc)TC(pc))T(Y-T(pc)TC(pc))/VarY, where
T(pc) is the pcth column of T, C(pc) is the pcth row of C transposed to a column vector, and
VarY is the variance of Y*. The VIP score is calculated for each measurement and total
number of pcs in the model (this ranking method substitutes for Step 6 in the SMR
algorithm). Step 7 is then performed based on VIP-score model reduction.
Missing data techniques for stochastic multivariate regression
The data matrices refer to matrices defined in the SMR section.
1. List-wise deletion. Delete each column of X and Xstd, corresponding to
measurements for variable m, that contains one or more missing sample
observation. Proceed with SMR.
2. Merge complete subset models. This method was specific to the HFDB data subset
of phosphotyrosine measurements, XHFDB, and XHFDB was divided into three
distinct blocks of complete data subsets, as shown in Figure S7A. SMR was used to
build individual models for each of the subsections, referred to as the “Complete”
(in which data exists for all sample conditions), “Run 1”, and “Run 2” subset
models. (“Run 1” and “Run 2” models each had data for at least 8 out of 13
conditions.) The results from the three models were combined using two sets of
rules. The first rule is referred to as “All subsets agree”, because a variable was
incorporated into a final model only if it was significant to sub-models from all
data subsets containing that measurement. Specifically, we select a variable for the
final model only if the significance of its regression coefficient, pm, is less than a
pre-determined significance cut-off, pcutoff ∈ [0,1], for all models incorporating that
measurement. The second rule is referred to as “Complete subset rules”, because
the “Complete” subset model takes priority in determining variable significance
and final model inclusion. If the variable is in the complete subset, select it for the
final model if pm < pcutoff. Otherwise, if the variable is in “Run 1” or “Run 2”
subset only, retain this variable in the model with the same criteria: if pm < pcutoff.
3. Gaussian Multiple Random Imputation (MRI) Methods (General, Treatment, and
P-value). In “General” Gaussian MRI, the missing samples for a measurement are
imputed from those available by drawing a Gaussian sample whose mean and
standard deviation correspond to the available sample measurements. This single
random imputation step is repeated multiple times. Conveniently, such an
Miraldi et al. Page 28
Integr Biol (Camb). Author manuscript; available in PMC 2014 July 24.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
imputation step seamlessly integrates into the SMR algorithm, as the imputation
step can immediately follow the Gaussian sampling step (Step 1, see schematic in
Figure S7B). “Treatment” Gaussian MRI makes use of treatment (e.g., genotype)
information when imputing missing datapoints. In “Treatment” Gaussian MRI,
only the values from samples with the same treatment conditions are used to impute
the missing values. For this dataset, missing data points corresponding to L-PTP1b
−/− mice were sampled from a Gaussian distribution whose mean and standard
deviation corresponded to the L-PTP1b−/− samples present for that measurement,
and missing control sample values were randomly imputed from a Gaussian
distribution based on control samples. In “P-value” Gaussian MRI, missing
datapoints are imputed using either “General” or “Treatment” Gaussian MRI,
contingent on ANOVA, in which a treatment-dependent effect is tested at a user-
specified significance threshold. If the measurement is significantly treatment
dependent, inferred conditions are imputed using “Treatment” MRI; otherwise,
“General” MRI is used. For the L-PTP1b−/− dataset, a two-sided Student t test
comparison of L-PTP1b−/− and control phosphorylation levels (at α = .05
significance level) was performed on the measured samples, and treatment-
dependent or treatment-independent MRI was used to impute missing values,
contingent on associate p-values.
4. Traditional MRI Methods (General, Treatment, and P-value). The traditional MRI
methods are identical to Gaussian MRI methods, except that the value used to
replace missing data points is randomly selected from those samples available, with
equal probability.
Evaluation of missing data techniques
Simulation of missing data—To evaluate missing data techniques specifically for SMR
with the HFDB phosphotyrosine dataset as the independent variable matrix, X, we utilized
the complete data subset of X. The full dataset (Figure 6B) contained 228 phosphosite
measurements across 13 samples, while the complete data subset contained 76 phosphosite
measurements across the same number of samples. We simulated 10 incomplete datasets
from the complete data subset, by randomly removing sections of phosphosite data so that,
structurally, the simulated incomplete datasets corresponded to the original dataset, although
with fewer samples (Figure 6B). In particular, for randomly selected measurement columns
in X, we ensured that 33% had complete data, 45% had data missing for 5 samples, 17% had
data missing for 5 other samples, and 5% of the columns had data missing for 7 of the 13
samples.
Construction of ROC curves—The complete data subset was used as the gold standard,
and three models were built using SMR for steatosis, ω3+ω6 PTP1b-dependent PUFA, and
ω7+ω9 PTP1b-dependent PUFA. As described in the SMR protocol, final models were
selected by (1) ranking all the phosphosite measurements according to regression coefficient
significance and (2) selecting the optimal number of measurements as judged by predictive
Q4 value. Those measurements selected for a final model served as true positives, and those
measurements excluded from a model served as true negatives.
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The nine missing data methods (described above) were used to build the three phenotype
models from each of the 10 simulated datasets. True positive rate (TPR) and false positive
rate (FPR) were calculated for each model and simulated dataset, as parametric functions of
a decision rule. We applied the following decision rule: include a measurement in the final
model if the significance of the associated regression coefficient is less than pcutoff. To build
ROC curves, we varied pcutoff from 0 to 1 and counted true positives and false positives
relative to the complete data (gold standard) models. TPR(pcutoff) and FPR(Pcutoff) curves
were averaged across simulated missing datasets for each model and plotted in Figure 6C.
Final models
Individual models of steatosis, ω3+ω6 PTP1b-dependent PUFA, and ω7+ω9 PTP1b-
dependent PUFA as functions of the complete HFDB phosphotyrosine dataset [228
phosphosites X 13 samples] were constructed using SMR and “Treatment” Traditional MRI;
these models were built using 1, 2, and 1 principle component(s), respectively.
Calculation of R2 and Q4—Estimation of model predictions for the response vector Y,
using the relationship Y = XB, requires a complete set of predictor variables X. Thus, to
estimate R2 and Q4 for the models a complete matrix, Xc, was created using column-wise
treatment-dependent mean imputation. Specifically, for each measurement (column) of Xc,
the missing data points for L-PTP1b−/− (or control) samples were estimated as the mean of
those L-PTP1b−/− (or control) samples observed for that measurement. Final model
parameters, pcs and F, were determined based on optimization of Q4 values. Estimation of
the error associated with the Q4 values was accomplished by leave-two-out cross-validation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Study Design and Phosphotyrosine Analysis
(A) Study design.
(B) Eight peptide samples, purified from individual livers, were chemically labeled
individually with a unique 8-plex iTRAQ isobaric mass tag. Labeled peptide samples were
combined and phosphotyrosine-containing peptides were enriched by phosphotyrosine
peptide IP using pan-specific phosphotyrosine antibodies. Phosphorylated peptides were
further enriched by IMAC prior to analysis by LC-MS/MS, resulting in hundreds of MS/MS
phosphopeptide fragmentation spectra. Each MS/MS spectrum yields (1) sequence
information and (2) iTRAQ reporter peaks whose intensities are proportional to the
abundance of that particular phosphopeptide in the corresponding samples. To enable
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phosphopeptide quantification across multiple 8-plex MS experiments, each experiment was
normalized to a control liver peptide sample, kept constant across experiments.
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Figure 2. Diet and Genotype Dependencies in the Phosphotyrosine Network
(A) Insulin-stimulated and basal liver samples are plotted in the principal component plane
as a function of mean-normalized tyrosine phosphorylation profiles.
(B) Heatmaps of the phosphorylation sites most significantly correlated to genotype (raw,
context-specific p-value < .025, see Methods). For basal or insulin datasets, the
phosphorylation level of a phosphosite was normalized to the corresponding phosphosite
mean (basal or insulin) and then log2-transformed. Missing data points are denoted by grey
dots over white boxes. Red asterisks denote lipid metabolic enzymes. The phosphosites are
separated into two clusters, depending on whether phosphorylation on those sites increases
or decreases upon PTP1b deletion.
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Figure 3. Global Lipidomics Analysis for De Novo Discovery
(A) Lipids were chloroform-extracted from individual livers. For absolute
quantification, 13C- or 2H-labeled standards were spiked into the chloroform phase and
endogenous lipids were quantified relative to standards. Lipid samples were individually
analyzed by LC-MS, creating a 3D lipidomics profile for each tissue sample.
(B) The software program, XCMS54, was used to identify differences in lipid profiles across
multiple analyses. Two representative ion chromatograms of the XCMS-detected and
PTP1b-dependent C20:3 FA isomers are superimposed.
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Figure 4. PTP1b-dependent Changes in Free Fatty Acid (FFA) Metabolism
(A) Volcano plot of % FA compositions on HFD (control, n = 19, L-PTP1b−/−, n = 17). P-
values are estimated by 2-sided t tests. The red line denotes P = .05, while the dotted grey
line shows the Bonferroni significance cut off to control for multiple hypotheses at FDR = .
05. Asterisks indicate uncertainty in FA ω-bond assignment.
(B) The clustered FA correlation matrix; the correlation coefficients between FAs were
calculated using % FA compositional measurements across NC and HFD mice.
(C) Mean +/− SEM C18 SCD indices. P-values are estimated using one-way ANOVA for
orthogonal comparisons of L-PTP1b−/− to control for each diet-stimulation condition; * and
^ denote P <.05 and .1.
(D) Western blot of hepatic pT172-AMPK, total AMPK, and β actin in HFD mice. The bar
graph represents mean +/− SEM pT172-AMPK to AMPK ratio from pooled basal and
insulin-stimulated samples. Significance was calculated using a 2-sided t test. * denotes P < .
05.
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Figure 5. PTP1b-dependent Changes in Triglyceride Metabolism
(A) Mean +/− SEM liver triglycerides (*** denotes P < .005).
(B) Scatter plot of liver triglycerides vs. body weight.
(C) Scatter plot of serum vs. liver triglycerides.
(D) Volcano plot of % triglyceride compositions on HFD (control, n = 10, L-PTP1b−/−, n =
6). The red line denotes P = .05, while the dotted grey line shows the Bonferroni
significance cut off to control for multiple hypotheses at FDR = .05.
(E) Affinity propagation clustering of z-scored triglyceride composition profiles. Missing
data points are denoted by grey dots over white boxes. P-values are estimated by 2-sided t
tests.
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Figure 6. Evaluation of SMR and Missing Data Methods
(A) Sets of phosphosites significant to three models (Genotype, Steatosis, C18 SCD Index).
Phosphosite significances were based on their associated multivariate regression
coefficients, as determined by SMR (Pstoch < .05) and DMR (Pdet < .05). Phosphosites
whose variation was distinguished from measurement error using ANOVA filtering are
included in Venn diagrams (PANOVA < .05).
(B) Schematic for testing missing data methods in the context of multivariate regression.
(C) Performance of strategies for incomplete data.
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Figure 7. Multivariate Models of Lipidomics Phenotypes
(A) The phosphosite and metabolite predictors that were included in final SMR models are
connected to phenotype nodes by edges whose widths reflect the importance of the
phosphosite or metabolite to the model. The (+) or (−) denotes the sign of predictors’
regression coefficient in the model. Final models were built using two model reduction
techniques, as denoted in the legend and described in Methods.
(B) Quantitative prediction (black) and fit (red) for ω7+w9 PTP1b-dependent PUFA,
steatosis and ω3+ω6 PTP1b-dependent PUFA models using model reduction by regression
coefficient significance (see Methods). Error bars denote experimental and model SEM.
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Figure 8. Proposed molecular and physiological model of L-PTP1b−/− lipid metabolism
Proposed interactions among phosphotyrosine network state, lipid metabolism, and
physiological phenotypes. Physiological processes in white boxes were not measured in this
study but would provide further insight into the phenotypes of L-PTP1b−/− mice on HFD.
“(+)” indicates that phosphorylation on a particular site is increased in L-PTP1b−/− mice.
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